cobra: ctdna to help decide which patients with colon cancer will benefit from adjuvant chemotherapy
Published 2 years ago • 547 plays • Length 4:31Download video MP4
Download video MP3
Similar videos
-
2:31
dynamic: ctdna guiding adjuvant chemotherapy in stage ii colon cancer
-
2:30
how can we use ctdna to improve adjuvant treatment for colon cancer?
-
2:43
real-world impact of adjuvant chemotherapy on patients with pt4n0 colon cancer
-
3:16
the utility of ctdna in colorectal cancer management
-
2:05
challenges to be overcome in the use of ctdna for colon cancer treatment
-
3:48
using ctdna to guide adjuvant therapy in stage ii colorectal cancer
-
6:58
personalizing ctdna analysis to predict crc relapse
-
2:53
the emerging role of mrd in colorectal cancer decision making
-
3:41
circulate-us: investigating the use of ctdna to detect mrd
-
3:29
ctdna and cfdna : prognostic value in the neoadjuvant setting of colon cancer
-
2:47
real-world monitoring of ctdna reliably predicts cancer recurrence in resected stages i-iii crc
-
8:18
the use of ctdna in patient cancer care
-
5:33
circulating tumour dna analysis can help identify the need for ct in stage ii colon cancer
-
8:04
“circulate” clinical trial evaluating ctdna dynamics and clinical outcomes in colon cancer
-
12:01
debate: is circulating tumor dna ready to guide adjuvant therapy in colon cancer? - yes
-
0:58
real-world monitoring of circulating tumor dna to predict cancer recurrence
-
3:54
circulating tumour dna analysis can help identify the need for adjuvant ct in stage ii colon cancer
-
3:30
ctdna as an mrd biomarker for nsclc
-
1:13
dr. morris on the design of the cobra trial in stage ii colon cancer